Pattern recognition receptors for respiratory syncytial virus infection and design of vaccines

Virus Research

Volumn 167, Issue 2, 2012, Pages 138-145

  Zeng, Ruihong ^a   Cui, Yuxiu ^a   Hai, Yan ^a   Liu, Ying ^a,b  

^a HEBEI MEDICAL UNIVERSITY   (China)

^b Cangzhou Medical College   (China)

Author keywords

Design of vaccines; Innate immune cells; NOD like receptor; Respiratory syncytial virus; RIG I like receptors; Toll like receptors

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; CASPASE RECRUITMENT DOMAIN PROTEIN 15; CD36 ANTIGEN; CPG OLIGODEOXYNUCLEOTIDE; DECTIN 1; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERFERON REGULATORY FACTOR 3; INTERLEUKIN 13; INTERLEUKIN 17; INTERLEUKIN 4; INTERLEUKIN 4 RECEPTOR ALPHA; MITOGEN ACTIVATED PROTEIN KINASE; NUCLEOTIDE BINDING OLIGOMERIZATION DOMAIN LIKE RECEPTOR; PROTEIN; RANTES; REACTIVE OXYGEN METABOLITE; RESPIRATORY SYNCYTIAL VIRUS VACCINE; RETINOIC ACID INDUCIBLE PROTEIN I; RETINOIC ACID INDUCIBLE PROTEIN I LIKE RECEPTOR 1; STAT6 PROTEIN; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 5; TOLL LIKE RECEPTOR 6; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 8; TOLL LIKE RECEPTOR 9; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

CYTOKINE PRODUCTION; CYTOKINE RELEASE; DENDRITIC CELL; EOSINOPHIL; HUMAN; INNATE IMMUNITY; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RESPIRATORY SYNCYTIAL VIRUS INFECTION; REVIEW; SIGNAL TRANSDUCTION; VIRUS LOAD;

HUMANS; IMMUNITY, INNATE; RECEPTORS, PATTERN RECOGNITION; RESPIRATORY SYNCYTIAL VIRUS VACCINES; RESPIRATORY SYNCYTIAL VIRUS, HUMAN; RESPIRATORY TRACT INFECTIONS;

RESPIRATORY SYNCYTIAL VIRUS; RICE STRIPE VIRUS;

EID: 84863871100     PISSN: 01681702     EISSN: 18727492     Source Type: Journal    
DOI: 10.1016/j.virusres.2012.06.003     Document Type: Review

References (108)

1. Aeffner F., Traylor Z.P., Yu E.N., Davis I.C. Double-stranded RNA induces similar pulmonary dysfunction to respiratory syncytial virus in BALB/c mice. American Journal of Physiology Lung Cellular and Molecular Physiology 2011, [Epub ahead of print, April 8].
2. Akira S., Uematsu S., Takeuchi O. Pathogen recognition and innate immunity. Cell 2006, 124:783-801.
3. Amanatidou V., Apostolakis S., Spandidos D.A. Genetic diversity of the host and severe respiratory syncytial virus-induced lower respiratory tract infection. Pediatric Infectious Disease Journal 2009, 28:135-140.
4. Asano J., Tada H., Onai N., Sato T., Horie Y., Fujimoto Y., Fukase K., Suzuki A., Mak T.W., Ohteki T. Nucleotide oligomerization binding domain-like receptor signaling enhances dendritic cell-mediated cross-priming in vivo. Journal of Immunology 2010, 184:736-745.
5. Awomoyi A.A., Rallabhandi P., Pollin T.I., Lorenz E., Sztein M.B., Boukhvalova M.S., Hemming V.G., Blanco J.C.G., Vogel S.N. Association of TLR4 polymorphisms with symptomatic respiratory syncytial virus infection in high-risk infants and young children. Journal of Immunology 2007, 179:3171-3177.
6. Banasal K., Balaii K.N. Intracellular pathogen sensor NOD2 programs macrophages to trigger Notch1 activation. The Journal of Biological Chemistry 2010, [Epub ahead of print, December 14].
7. Bermejo-Martin J.F., Garcia-Arevalo M.C., Alonso A., De Lejarazu R.O., Pino M., Resino S., Tenorio A., Bernardo D., Leon A.J., Garrote J.A., et al. Persistence of proinflammatory response after severe respiratory syncytial virus disease in children. Journal of Allergy and Clinical Immunology 2007, 119:1547-1550.
8. Bhoj V.G., Sun Q., Bhoj E.J., Somers C., Chen X., Torres J., Mejias A., Gomez A.M., Jafri H., Ramilo O., et al. MAVS and MyD88 are essential for innate immunity but not cytotoxic T lymphocyte response against respiratory syncytial virus. Proceedings of the National Academy of Sciences 2008, 105:14046-14051.
9. Blanco J.C.G., Boukhvalova M.S., Shirey K.A., Prince G.A., Vogel S.N. New insights for development of a safe and protective RSV. Vaccine: Human Vaccines 2010, 6(6):482-492.
10. Boogaard I., van Oosten M., van Rijt L.S., Muskens F., Kimman T.G., Lambrecht B.N., Buisman A.M. Respiratory syncytial virus differentially activates murine myeloid and plasmacytoid dendritic cells. Immunology 2007, 122:65-72.
11. Boukhvalova M.S., Prince G.A., Soroush L., Harrigan D.C., Vogel S.N., Blanco J.C.G. The TLR4 agonist, monophosphoryl lipid A, attenuates the cytokine storm associated with respiratory syncytial virus vaccine-enhanced disease. Vaccine 2006, 24:5027-5035.
12. Carroll K.N., Wu P., Gebretsadik T., Griffin M.R., Dupont W.D., Mitchel E.F., Hartert T.V. The severity-dependent relationship of infant bronchiolitis on the risk and morbidity of early childhood asthma. Journal of Allergy and Clinical Immunology 2009, 123:1055-1061.
13. Castro S.M., Chakraborty K., Guerrero-Plata A. Cigarette smoke suppresses TLR-7 stimulation in response to virus infection in plasmacytoid dendritic cells. Toxicology in Vitro 2011, 25(5):1106-1113.
14. Cepika A.M., Gagro A., Bace A., Tjesic-Drinkovic D., Kelecic J., Baricic-Voskresensky T., Matic M., Drazenovic V., Marinic I., Mlinaric-Galinovic G., et al. Expression of chemokine receptor CX3CR1 in infants with respiratory syncytial virus bronchiolitis. Pediatric Allergy and Immunology 2008, 19:148-156.
15. Chen G., Shaw M.H., Kim Y.G., Nunez G. Nod-like receptors: role in innate immunity and inflammatory disease. Annual Review of Pathology 2009, 4:365-398.
16. Choi J., Callaway Z., Kim H.B., Fujisawa T., Kim C.K. The role of TNF-α in eosinophilic inflammation associated with RSV bronchiolitis. Pediatric Allergy and Immunology 2010, 21:474-479.
17. Collins P.L., Chanock R.M., Murphy B.R. Respiratory Syncytial Virus Disease, Fields in Virology 2001, 1443-1486. 4th ed. D. Knipe, P. Howley (Eds.).
18. Collins P.L., Melero J.A. Progress in understanding and controlling respiratory syncytial virus: still crazy after all these years. Virus Research 2011, 162(1-2):80-99.
19. Cyr S.L., Angers I., Guillot L., Stoica-Popescu I., Lussier M., Qureshi S., Burt D.S., Ward B.J. TLR4 and MyD88 control protection and pulmonary granulocytic recruitment in a murine intranasal RSV immunization and challenge model. Vaccine 2009, 27:421-430.
20. Cyr S.L., Jones T., Stoica-Popescu I., Brewer A., Chabot S., Lussier M., et al. Intranasal proteosome-based respiratory syncytial virus (RSV) vaccines protect BALB/c mice against challenge without eosinophilia or enhanced pathology. Vaccine 2007, 25(29):5378-5389.
21. Cyr S.L., Jones T., Stoica-Popescu I., Burt D., Ward B.J. C57Bl/6 mice are protected from respiratory syncytial virus (RSV) challenge and IL-5 associated pulmonary eosinophilic infiltrates following intranasal immunization with Protollin-eRSV vaccine. Vaccine 2007, 25(16):3228-3232.
22. Delgado M.F., Coviello S., Monsalvo A.C., Melendi G.A., Hernandez J.Z., Batalle J.P., Diaz L., Trento A., Chang H., Mitzner W. Lack of antibody affinity maturation due to poor Toll-like receptor stimulation leads to enhanced respiratory syncytial virus disease. Nature Medicine 2009, 15:34-41.
23. Diebold S.S., Kaisho T., Hemmi H., Akira S., Sousa C.R. Innate anti-viral responses via TLR7-mediated recognition of single stranded RNA. Science 2004, 303:1529-1531.
24. Ehl S., Bischoff R., Ostler T., Vallbracht S., Schulte-Monting J., Poltorak A., Freudenberg M. The role of toll-like receptor 4 versus interleukin-12 in immunity to respiratory syncytial virus. European Journal of Immunology 2004, 34:1146-1153.
25. Eisenbarth S.C., Colegio O.R., O'Connor W., Sutterwala F.S., Flavell R.A. Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants. Nature 2008, 453(7198):1122-1126.
26. Fujita T., Onoguchi K., Onomoto K., Hirai R., Yoneyama M. Triggering antiviral response by RIG-I-related RNA helicases. Biochimie 2007, 89:754-760.
27. Gagro A., Tominac M., Krsulovic-Hresic V., Bace A., Matic M., Drazenovic V., Mlinaric-Galinovic G., Kosor E., Gotovac K., Bolanca I., et al. Increased Toll-like receptor 4 expression in infants with respiratory syncytial virus bronchiolitis. Clinical and Experimental Immunology 2004, 135:267-272.
28. Groskreutz D.J., Monick M.M., Powers L.S., Yarovinsky T.O., Look D.C., Hunninghake G.W. Respiratory syncytial virus induces TLR3 protein and protein kinase R, leading to increased double-stranded RNA responsiveness in airway epithelial cells. Journal of Immunology 2006, 176:1733-1740.
29. Haeberle H.A., Takizawa R., Casola A., Brasier A.R., Dieterich H.J., Van Rooijen N., Gatalica Z., Garofalo R.P. Respiratory syncytial virus-induced activation of nuclear factor-kappaB in the lung involves alveolar macrophages and toll-like receptor 4-dependent pathways. Journal of Infectious Diseases 2002, 186(November):1199-1206.
30. Haerberle H.A., Takizawa R., Casola A., Brasier A.R., Dieterich H.J., Van Rooijen N., Gatalica Z., Garofalo R.P. Respiratory syncytial virus-induced activation of nuclear factor-kappa B in the lung involves alveolar macrophages and Toll like receptor 4-dependant pathways. Journal of Infectious Diseases 2002, 1869:1199-1206.
31. Halfhide C.P., Brearey S.P., Flanagan B.F., Hunt J.A., Howarth D., Cummerson J., Edwards S., Hart C.A., Smyth R.L. Neutrophil TLR4 expression is reduced in the airways of infants with severe bronchiolitis. Thorax 2009, 64:798-805.
32. Hayashi F., Means T.K., Luster A.D. Toll-like receptors stimulate human neutrophil function. Blood 2003, 102:2660-2669.
33. Haynes L.M., Moore D.D., Kurt-Jones E.A., Finberg R.W., Anderson L.J., Tripp R.A. Involvement of toll-like receptor 4 in innate immunity to respiratory syncytial virus. Journal of Virology 2001, 75:10730-10737.
34. Higgins S.C., Mills K.H. TLR, NLR agonists, and other immune modulators as infectious disease vaccine adjuvants. Current Infectious Diseases Reports 2010, 12(1):4-12.
35. Hornung V., Ellegast J., Kim S., Brzozka K., Jung A., Kato H., Poeck H., Akira S., Conzelmann K.K., Schlee M., et al. 50-Triphosphate RNA is the ligand for RIG-I. Science 2006, 314:994-997.
36. Hornung V., Schlender J., Guenthner-Biller M., Rothenfusser S., Endres S., Conzelmann K.K., Hartmann G. Replication-dependent potent IFN-α induction in human plasmacytoid dendritic cells by a single-stranded RNA virus. Journal of Immunology 2004, 173:5935-5943.
37. Huang Y., Cyr S.L., Burt D.S., Anderson R. Murine host responses to respiratory syncytial virus (RSV) following intranasal administration of a Protollin-adjuvanted, epitope-enhanced recombinant G protein vaccine. Journal of Clinical Virology 2009, 44:287-291.
38. Jamaluddin M., Tian B., Boldogh I., Garofalo R.P., Brasier A.R. Respiratory syncytial virus infection induces a reactive oxygen species-MSK1-Phospho-Ser-276 RelA pathway required for cytokine expression. Journal of Virology 2009, 83:10605-10615.
39. Jewell N.A., Vaghefi N., Mertz S.E., Akter P., Peebles R.S., Bakaletz L.O. Differential type I interferon induction by respiratory syncytial virus and influenza A virus in vivo. Journal of Virology 2007, 81:9790-9800.
40. Johnson T.R., Johnson C.N., Corbett K.S., Edwards G.C., Graham B.S. Primary human mDC1, mDC2, and pDC dendritic cells are differentially infected and activated by respiratory syncytial virus. PLoS One 2011, 6(1):e16458.
41. Johnson T.R., Rao S., Seder R.A., Chen M., Graham B.S. TLR9 agonist, but not TLR7/8, functions as an adjuvant to diminish FI-RSV vaccine-enhanced disease, while either agonist used as therapy during primary RSV infection increases disease severity. Vaccine 2009, 27:3045-3052.
42. Juarez E., Nuñez C., Sada E., Ellner J.J., Schwander S.K., Torres M. Differential expression of Toll-like receptors on human alveolar macrophages and autologous peripheral monocytes. Respiratory Research 2010, 10.1186/1465-9921-11-2.
43. Kapikian A.Z., Mitchell R.H., Chanock R.M., Shvedoff R.A., Stewart C.E. An epidemiologic study of altered reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine. American Journal of Epidemiology 1969, 89:405-421.
44. Kato H., Sato S., Yoneyama M., Yamamoto M., Uematsu S., Matsui K., Tsujimura T., Takeda K., Fujita T., Takeuchi O., Akira S. Cell type-specific involvement of RIG-I in antiviral response. Immunity 2005, 23:19-28.
45. Kim H.H., Lee M.H., Lee J.S. Eosinophil cationic protein and chemokines in nasopharyngeal secretions of infants with respiratory syncytial virus (RSV) bronchiolitis and non-RSV bronchiolitis. Journal of Korean Medical Science 2007, 22:37-42.
46. Krieg A. TLR9 and DNA "feel" rage. Nature Immunology 2007, 8:475-477.
47. Kumar H., Kawai T., Akira S. Toll-like receptors and innate immunity. Biochemical and Biophysical Research Communications 2009, 388:621-625.
48. Kurt-Jones E.A., Popova L., Kwinn L., Haynes L.M., Jones L.P., Tripp R.A., Walsh E.E., Freeman M.V.V., Golenbock D.T., Anderson L.J., et al. Pattern recognition receptors TLR4 and CD14 mediate response to respiratory syncytial virus. Nature Immunology 2000, 1:398-401.
49. Le Nouën C., Munir S., Losq S., Winter C.C., McCarty T., Stephany D.A., Holmes K.L., Bukreyev A., Rabin R.L., Collins P.L., et al. Infection and maturation of monocyte-derived human dendritic cells by human respiratory syncytial virus, human metapneumovirus, and human parainfluenza virus type 3. Virology 2009, 385:169-182.
50. Lee A., Whyte M.K., Haslett C. Inhibition of apoptosis and prolongation of neutrophil functional longevity by inflammatory mediators. Journal of Leukocyte Biology 1993, 54:283-288.
51. Leulier F., Lemaitre B. Toll-like receptors-taking an evolutionary approach. Nature Reviews Genetics 2008, 9:165-178.
52. Lindell D.M., Lukacs N.W. Protective and pathologic host responses to pulmonary respiratory syncytial virus infection. RNA Viruses: Host Gene Responses to Infections 2009, 191. World Scientific Publishing Co. Pte. Ltd., Singapore. D. Yang (Ed.).
53. Lindell D.M., Morris S., Mukherjee S., Lukacs N.W. TLR-7 mediated responses to respiratory syncytial virus (RSV). Journal of Immunology 2009, 182:133-145.
54. Lindemans C.A., Coffer P.J., Schellens I.M., de Graaff P.M., Kimpen J.L., Koenderman L. Respiratory syncytial virus inhibits granulocyte apoptosis through a phosphatidylinositol 3-kinase and NF-kappaB dependent mechanism. Journal of Immunology 2006, 176:5529-5537.
55. Lindemans C.A., Kimpen J.L., Luijk B., Heidema J., Kanters D., van der Ent C.K., Koenderman L. Systemic eosinophil response induced by respiratory syncytial virus. Clinical and Experimental Immunology 2006, 144:409-417.
56. Ling Z., Tran K.C., Teng M.N. Human respiratory syncytial virus nonstructural protein NS2 antagonizes the activation of beta interferon transcription by interacting with RIG-I. Journal of Virology 2009, 83:3734-3742.
57. Liu P., Jamaluddin M., Li K., Garofalo R.P., Casola A., Brasier A.R. Retinoic acid-inducible gene I mediates early antiviral response and Toll-like receptor 3 expression in respiratory syncytial virus-infected airway epithelial cells. Journal of Virology 2007, 81:1401-1411.
58. Liu P., Li K., Garofalo R.P., Brasier A.R. Respiratory syncytial virus induces RelA release from cytoplasmic 100-kDa NF-κB2 complexes via a novel retinoic acid-inducible gene-I·NF-κB-inducing kinase signaling pathway. Journal of Biological Chemistry 2008, 283:23169-23178.
59. Lukacs N.W., Smit J.J., Mukherjee S., Morris S.B., Nunez G., Lindell D.M. Respiratory virus-induced TLR7 activation controls IL-17-associated increased mucus via IL-23 regulation. Journal of Immunology 2010, 185:2231-2239.
60. Lukens M.V., Kruiisen D., Coenjaerts F.E., Kimpen J.L., van Bleek G.M. Respiratory syncytial virus-induced activation and migration of respiratory dendritic cells and subsequent antigen presentation in the lung-draining lymph node. Journal of Virology 2009, 83:7235-7243.
61. Mandelberg A., Tal G., Naugolny L., Cesar K., Oron A., Houri S., Gilad E., Somekh E. Lipopolysaccharide hyporesponsiveness as a risk factor for intensive care unit hospitalization in infants with respiratory syncytial virus bronchiolitis. Clinical and Experimental Immunology 2006, 144:48-52.
62. Medzhitov R. Recognition of microorganisms and activation of the immune response. Nature 2007, 449:819-826.
63. Millmann-Born S., Lipinski S., Bock J., Till A., Rosenstiel P., Schreiber S. The complex interplay of NOD-like receptors and the autophagy machinery in the pathophysiology of Crohn disease. European Journal of Cell Biology 2010, [Epub ahead of print, December 9].
64. Mills K.H.G. Designer adjuvants for enhancing the efficacy of infectious disease and cancer vaccines based on suppression of regulatory T cell induction. Immunology Letters 2009, 122:108-111.
65. Mohapatra S.S., Boyapalle S. Epidemiologic, experimental, and clinical links between respiratory syncytial virus infection and asthma. Clinical Microbiology Reviews 2008, 21:495-504.
66. Monick M.M., Yarovinsky T.O., Powers L.S., Butler N.S., Carter A.B., Gudmundsson G., Hunninghake G.W., et al. Respiratory syncytial virus upregulates TLR4 and sensitizes airway epithelial cells to endotoxin. Journal of Biological Chemistry 2003, 278:53035-53044.
67. Moreira L.O., Smith A.M., DeFreitas A.A., Qualls J.E., Kasmi K.C.E., Murray P.J. Modulation of adaptive immunity by different adjuvant-antigen combinations in mice lacking Nod2. Vaccine 2008, 26:5808-5813.
68. Murawski M.R., Bowen G.N., Cerny A.M., Anderson L.J., Haynes L.M., Tripp R.A., Kurt-jone E.A., Finberg R.W. Respiratory syncytial virus activates innate immunity through Toll-like receptor 2. Journal of Virology 2009, 83:1492-1500.
69. Nagase H., Okugawa S., Ota Y., Yamaguchi M., Tomizawa H., Matsushima K., Ohta K., Yamamoto K., Hirai K. Expression and function of Toll-like receptors in eosinophils: activation by Toll-like receptor 7 ligand. Journal of Immunology 2003, 171:3977-3982.
70. Numata M., Chu H.W., Dakhama A., Voelker D.R. Pulmonary surfactant phosphatidylglycerol inhibits respiratory syncytial virus-induced inflammation and infection. Proceedings of the National Academy of Sciences of the United States of America 2010, 107:320-325.
71. Ohto U., Fukase K., Miyake K., Satow Y. Crystal structures of human MD-2 and its complex with antiendotoxic lipid IVa. Science 2007, 316:1632-1634.
72. Oumouna M., Mapletoft J.W., Karvonen B.C., Babiuk L.A., van Drunen Littelvan den Hurk S. Formulation with CpG oligodeoxynucleotides prevents induction of pulmonary immunopathology following priming with formalin-inactivated or commercial killed bovine respiratory syncytial virus vaccine. Journal of Virology 2005, 79:2024-2032.
73. Phipps S., Lam C.E., Mahalingam S., Newhouse M., Ramirez R., Rosenberg H.F., Foster P.S., Matthaei K.I. Eosinophils contribute to innate antiviral immunity and promote clearance of respiratory syncytial virus. Blood 2007, 110:1578-1586.
74. Pribul P.K., Harker J., Wang B., Wang H., Tregoning J.S., Schwarze J., Openshaw P.J. Alveolar macrophages are a major determinant of early responses to viral ling infection but do not influence subsequent disease development. Journal of Virology 2008, 82:4441-4448.
75. Resch B., Gusenleitner W., Mueller W.D. Risk of concurrent bacterial infection in preterm infants hospitalized due to respiratory syncytial virus infection. Acta Paediatrica 2007, 96:495-498.
76. Rudd B.D., Burstein E., Duckett C.S., Li X., Lukacs N.W. Differential role for TLR3 in respiratory syncytial virus-induced chemokine expression. Journal of Virology 2005, 79:3350-3357.
77. Rudd B.D., Schaller M.A., Smit J.J., Kunkel S.L., Neupane R., Kelley L., Berlin A.A., Lukacs N.W. MyD88-mediated instructive signals in dendritic cells regulate pulmonary immune responses during respiratory virus infection. Journal of Immunology 2007, 178:5820-5827.
78. Rudd B.D., Smit J.J., Flavell R.A., Alexopoulou L., Schaller M.A., Gruber A., Berlin A.A., Lukacs N.W. Deletion of TLR3 alters the pulmonary immune environment and mucus production during respiratory syncytial virus infection. Journal of Immunology 2006, 176:1937-1942.
79. Sabbah A., Chang T.H., Harnack R., Frohlich V., Tominaga K., Dube P.H., Xiang Y., Bose S. Activation of innate immune antiviral responses by Nod2. Nature Immunology 2009, 10:1073-1080.
80. Scagnolari C., Midulla F., Pierangeli A., Moretti C., Bonci E., Berardi R., Angelis D.D., Selvaggi C., Marco P.D., Girardi E., et al. Gene expression of nucleic acid-sensing pattern recognition receptors in children hospitalized for respiratory syncytial virus-associated acute bronchiolitis. Clinical and Vaccine Immunology 2009, 16:816-823.
81. Schlender J., Hornung V., Finke S., Gunthner-Biller M., Marozin S., Brzoózka K., Moghim S., Endres S., Hartmann G., Conzelmann K.K. Inhibition of Toll-like receptor 7- and 9-mediated alpha/beta interferon production in human plasmacytoid dendritic cells by respiratory syncytial virus and measles virus. Journal of Virology 2005, 79:5507-5515.
82. Schmidt A.C., Johnson T.R., Openshaw P.J., Braciale T.J., Falsey A.R., Anderson L.J., et al. Respiratory syncytial virus and other pneumoviruses: a review of the international symposium-RSV 2003. Virus Research 2004, 106(1):1-13.
83. Senft A.P., Taylor R.H., Lei W., Campbell S.A., Tipper J.L., Martinez M.J., Witt T.L., Clay C.C., Harrod K.S. Respiratory syncytial virus impairs macrophage IFN-alpha/beta- and IFN-gamma-stimulated transcription by distinct mechanisms. American Journal of Respiratory Cell and Molecular Biology 2010, 42:404-414.
84. Shafique M., Wilschut J., Haan A. de Induction of mucosal and systemic immunity against respiratory syncytial virus by inactivated virus supplemented with TLR9 and NOD2 ligands. Vaccine 2012, 30:597-606.
85. Shimojo Y.I.N., Arima T., Kohno Y. Toll-like receptor 2 as a functional receptor to respiratory syncytial virus. Journal of Allergy and Clinical Immunology 2006, S210:809 (Abstracts).
86. Shirey K.A., Pletneva L.M., Puche A.C., Keegan A.D., Prince G.A., Blanco J.C.G., Voge S.N. Control of RSV-induced Lung Injury by Alternatively Activated Macrophages Is IL-4Rα-, TLR4-, and IFN-β-dependent. Mucosal Immunology 2010, 3:291-300.
87. Singh S.R., Dennis V.A., Carter C.L., Pillai S.R., Jefferson A., Sahi S.V., Moore E.G. Immunogenicity and efficacy of recombinant RSV-F vaccine in a mouse model. Vaccine 2007, 25:6211-6223.
88. Smit J.J., Lindell D.M., Boon L., Kool M., Lambrecht B.N., Lukacs N.W. The balance between plasmacytoid dc versus conventional dc determines pulmonary immunity to virus infections. PLoS One 2008, 3:e1720-e1728.
89. Smit J.J., Rudd B.D., Lukacs N.W. Plasmacytoid dendritic cells inhibit pulmonary immunopathology and promote clearance of respiratory syncytial virus. Journal of Experimental Medicine 2006, 203:1153-1159.
90. Suzuki T., Chow C., Downey G.P. Role of innate immune cells and their products in lung immunopathology. International Journal of Biochemistry & Cell Biology 2008, 40:1348-1361.
91. Tal G., Mandelberg A., Dalal I., Cesar K., Somekh E., Tal A., Oron A., Itskovich S., Ballin A., Houri S., et al. Association between common toll-like receptor 4 mutations and severe respiratory syncytial virus disease. Journal of Infectious Diseases 2004, 189:2057-2063.
92. The IMpact-RSV Study Group Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics 1998, 102:531-537.
93. Thompson L., Kolumam G., Thomas S., Murali-Krishna K. Innate inflammatory signals induced by various pathogens differentially dictate the IFN-I dependence of CD8 T cells for clonal expansion and memory formation. Journal of Immunology 2006, 177:1746-1754.
94. Thompson W.W., Shay D.K., Weintraub E., Brammer L., Cox N., Andreson L.F., Fukuda K. Mortality associated with influenza and respiratory syncytial virus in the United States. Journal of the American Medical Association 2003, 289:179-186.
95. Thornburg N.J., Shepherd B., Crowe J.E.J. Transforming growth factor beta is a major regulator of human neonatal immune responses following respiratory syncytial virus infection. Journal of Virology 2010, 84:12895-12902.
96. Ting J.P., Duncan J.A., Lei Y. How the noninflammasome NLRs function in the innate immune system. Science 2010, 327:286-290.
97. Ting J.P., Lovering R.C., Alnemri E.S., Bertin J., Boss J.M., Davis B.K., Flavell R.A., Girardin S.E., Godzik A., Harton J.A., et al. The NLR gene family: a standard nomenclature. Immunity 2008, 28:285-287.
98. Tulic M.K., Hurrelbrink R.J., Prele C.M., Laing I.A., Upham J.W., Le Sourf P., Sly P.D., Holt P.G. TLR4 polymorphisms mediate impaired responses to respiratory syncytial virus and lipopolysaccharide. Journal of Immunology 2007, 179:132-140.
99. Wang S.Z., Forsyth K.D. The interaction of neutrophils with respiratory epithelial cells in viral infection. Respirology 2000, 5:1-10.
100. Waris M.E., Tsou C., Erdman D.D., Zaki S.R., Anderson L.J. Respiratory syncytial virus infection in BALB/c mice previously immunized with formalin-inactivated virus induces enhanced pulmonary inflammatory response with a predominant Th2-like cytokine pattern. Journal of Virology 1996, 70:2852-2860.
101. Wheeler D.S., Chase M.A., Senft A.P., Poynter S.E., Wong H.R., Page K. Extracellular Hsp72, an endogenous DAMP, is released by virally infected airway epithelial cells and activates neutrophils via Toll-like receptor (TLR)-4. Respiratory Research 2009, 10:31. 10.1186/1465-9921-10-31.
102. Wu H., Dennis V.A., Pillai S.R., Singh S.R. RSV fusion (F) protein DNA vaccine provides partial protection against viral infection. Virus Research 2009, 145:39-47.
103. Yoboua F., Martel A., Duval A., Mukawera E., Grandvaux N. Respiratory syncytial virus-mediated NF-kappa B p65 phosphorylation at serine 536 is dependent on RIG-I, TRAF6, and IKK beta. Journal of Virology 2010, 84:7267-7277.
104. Yoneyama M., Fujita T. Structural mechanism of RNA recognition by the RIG-I-like receptors. Immunity 2008, 29:178-181.
105. Yoneyama M., Kikuchi M., Matsumoto K., Imaizumi T., Miyagishi M., Taira K., Foy E., Loo Y.M., Gale M.J., Akira S., et al. Shared and unique functions of the DExD/H-box helicases RIG-I, MDA5, and LGP2 in antiviral innate immunity. Journal of Immunology 2005, 175:2851-2858.
106. Zeng R., Zhang Z., Mei X., Gong W., Wei L. Protective effect of a RSV subunit vaccine candidate G1F/M2 was enhanced by a HSP70-like protein in mice. Biochemical and Biophysical Research Communications 2008, 377:495-499.
107. Zhang W., Boyapalle S., Cao X., Wang J., Lockey R.F., Mohapatra S.S. RSV NS1 protein blocks the IFN response by blocking RIG-I interaction with the mitochondrial antiviral signaling protein, MAVS. Journal of Allergy and Clinical Immunology 2009, S208 Abstracts.
108. Zheng Y., An H., Yao M., Hou J., Yu Y., Feng G., Cao X. Scaffolding adaptor protein Gab1 is required for TLR3/4- and RIG-I-mediated production of proinflammatory cytokines and type I IFN in macrophages. Journal of Immunology 2010, 184:6447-6456.